medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2023, Number 1

<< Back

Medicina & Laboratorio 2023; 27 (1)

Relationship between microbiota composition and essential hypertension. A narrative review

Rosario-Castro S, Rojas-García D, Pilar SI

Language: Spanish
References: 58
Page: 65-79
PDF size: 183.14 Kb.


ABSTRACT

Essential arterial hypertension is a highly prevalent pathology worldwide and is one of the most significant determinants of cardiovascular disease. On the other hand, great interest has been generated in the microbiota of the body, and how it is altered by both internal and external factors, causing dysbiosis. Currently, the effect of the microbiota in different diseases is being studied, including the relationship between the microbiota and hypertension. In this article, a review of the literature was made, between 2010 and 2021, with the objective of identifying the scientific evidence that supports the relationship between the composition of the microbiota and essential arterial hypertension. It was found in many studies that individuals with high blood pressure had lower microbiota diversity compared to healthy control groups. In hypertensive patients, bacteria of the genus Prevotella were mainly found, while in the control group the genus Bacteroidetes predominated. Additionally, a decrease in Faecalibacterium, Roseburia and Bifidobacterium was observed in the hypertensive group. There are several laboratory techniques for the analysis of the intestinal bacterial population, such as 16S rRNA subunit sequencing, whole genome sequencing, and microbiota metagenomics. Despite the fact that the studies conclude that there is a significant relationship between microbiota and hypertension, it is necessary to do more research in different population groups.


REFERENCES

  1. Williams B, Mancia G, Spiering W, Agabiti-Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterialhypertension: The Task Force for themanagement of arterial hypertension of theEuropean Society of Cardiology and the EuropeanSociety of Hypertension. J Hypertens 2018;36:1953-2041. https://doi.org/10.1097/hjh.0000000000001940.

  2. Wenzel U, Turner JE, Krebs C, Kurts C, HarrisonDG, Ehmke H. Immune mechanisms in arterialhypertension. J Am Soc Nephrol 2016;27:677-686. https://doi.org/10.1681/asn.2015050562.

  3. Canale MP, Noce A, Di Lauro M, Marrone G,Cantelmo M, Cardillo C, et al. Gut dysbiosisand western diet in the pathogenesis of essentialarterial hypertension: A narrative review.Nutrients 2021;13. https://doi.org/10.3390/nu13041162.

  4. Vallianou NG, Geladari E, Kounatidis D.Microbiome and hypertension: where arewe now? J Cardiovasc Med (Hagerstown)2020;21:83-88. https://doi.org/10.2459/jcm.0000000000000900.

  5. Felizardo RJ, Watanabe IK, Dardi P, RossoniLV, Câmara NO. The interplay among gut microbiota,hypertension and kidney diseases: Therole of short-chain fatty acids. Pharmacol Res2019;141:366-377. https://doi.org/10.1016/j.phrs.2019.01.019.

  6. Battson ML, Lee DM, Weir TL, Gentile CL. Thegut microbiota as a novel regulator of cardiovascularfunction and disease. J Nutr Biochem2018;56:1-15. https://doi.org/10.1016/j.jnutbio.2017.12.010.

  7. Marques FZ, Mackay CR, Kaye DM. Beyondgut feelings: how the gut microbiota regulatesblood pressure. Nat Rev Cardiol 2018;15:20-32.https://doi.org/10.1038/nrcardio.2017.120.

  8. Álvarez J, Fernández-Real JM, Guarner F,Gueimonde M, Rodríguez JM, Saenz-de PipaonM, et al. Microbiota intestinal y salud. GastroenterolHepatol 2021;44:519-535. https://doi.org/10.1016/j.gastrohep.2021.01.009.

  9. Mercedes D. Microbiota intestinal nutrición ysalud. Tendencias en Medicina Nº 57. Montevideo,Uruguay: Farmanuario; 2020. Acceso18 de agosto de 2022. Disponible en https://issuu.com/farmanuario/docs/tendencias_en_medicina_n__57_uruguay/s/12214945.

  10. Moreno-del Castillo MC, Valladares-GarcíaJ, Halabe-Cherem J. Microbioma humano.Rev Fac Med 2018;61:7-19. https://doi.org/10.22201.fm.24484865e.2018.61.6.02.

  11. Pevsner-Fischer M, Blacher E, Tatirovsky E,Ben-Dov IZ, Elinav E. The gut microbiomeand hypertension. Curr Opin Nephrol Hypertens2017;26:1-8. https://doi.org/10.1097/mnh.0000000000000293.

  12. Foratori-Junior GA, Máscoli LS, MarcheseCC, Orenha ES, Sales-Peres SH. Associationbetween arterial hypertension and periodontalstatus in morbidly obese patients who arecandidates for bariatric surgery. Int Dent J2021;71:242-249. https://doi.org/10.1111/idj.12625.

  13. Kotchen TA. Historical trends and milestonesin hypertension research: a model of the processof translational research. Hypertension2011;58:522-538. https://doi.org/10.1161/hypertensionaha.111.177766.

  14. Grupo de Trabajo de la Sociedad Europea deCardiología (ESC) y la European Society of Hypertension(ESH). Guía ESC/ESH 2018 sobre eldiagnóstico y tratamiento de la hipertensión arterial.Rev Esp Cardiol 2019;72:e160-161.e178.https://doi.org/10.1016/j.recesp.2018.12.005.

  15. World Health Organization (WHO). Clasificaciónestadística internacional de enfermedadesy problemas relacionados con la salud. Volumen2. Manual de instrucciones. Washington, D.C:OPS, Oficina Sanitaria Panamericana, OficinaRegional de la Organización Mundial de la Salud;2003. 10a edición. Acceso 15 de octubre de2022. Disponible en https://iris.paho.org/handle/10665.2/6283.

  16. Sauza-Sosa J, Cuéllar-Álvarez J, Villegas-Herrera K, Sierra-Galán L. Aspectos clínicosactuales del monitoreo ambulatorio de presiónarterial. Arch Cardiol Mex 2016;86:255-259.https://doi.org/10.1016/j.acmx.2015.12.004.

  17. Gamboa AR. Fisiopatología de la hipertensiónarterial esencial. Acta Med Peruana 2006;23:76-82.

  18. Prat H, Araos P, Michea L. La inflamación en lahipertensión arterial, mecanismos de produccióne implicancias terapéuticas. Rev Med Chile2021;149:255-262.

  19. Götzinger F, Kunz M, Lauder L, Böhm M, MahfoudF. Arterial hypertension - clinical trialsupdate 2022. Hypertens Res 2022;45:1140-1146. https://doi.org/10.1038/s41440-022-00931-2.

  20. Sandoya E, Torres F, Rivedieu F, Machado F,Núñez E. Situación de la hipertensión arteriala nivel público y privado. Rev Urug Cardiol2016;31:e6.

  21. Organización Mundial de la Salud (OMS).Información general sobre la hipertensión enel mundo. Una enfermedad que mata en silencio,una crisis de salud pública mundial.Día mundial de la salud 2013. Ginebra, Suiza:OMS; 2013. Acceso 13 de octubre de 2022.Disponible en https://apps.who.int/iris/bitstream/handle/10665/87679/WHO_DCO_WHD_2013.2_spa.pdf;jsessionid=5288364499C9D6B5623F76C6DB6F5E90?sequence=1.

  22. Mills KT, Stefanescu A, He J. The global epidemiologyof hypertension. Nat Rev Nephrol2020;16:223-237. https://doi.org/10.1038/s41581-019-0244-2.

  23. Anders HJ, Baumann M, Tripepi G, MallamaciF. Immunity in arterial hypertension: associationsor causalities? Nephrol Dial Transplant2015;30:1959-1964. https://doi.org/10.1093/ndt/gfv057.

  24. Organización Panamericana de la Salud(OPS). Hipertensión. Washington, DC: OPS;2022. Acceso 25 de agosto de 2022. Disponibleen https://www.paho.org/es/temas/hipertension.

  25. Ministerio de Salud y Protección Social(MinSalud). Día mundial de la hipertensiónarterial, Colombia–mayo 17 de 2017. FichaTécnica. Bogotá D.C.: MinSalud; 2017. Acceso20 de octubre de 2022. Disponible en https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ENT/dia-mundial-hipertension-2017.pdf.

  26. Hall JE, Granger JP, do Carmo JM, da SilvaAA, Dubinion J, George E, et al. Hypertension:physiology and pathophysiology. Compr Physiol2012;2:2393-2442. https://doi.org/10.1002/cphy.c110058.

  27. Intengan HD, Schiffrin EL. Vascular remodelingin hypertension: roles of apoptosis,inflammation, and fibrosis. Hypertension2001;38:581-587. https://doi.org/10.1161/hy09t1.096249.

  28. Xiao L, Harrison DG. Inflammation in hypertension.Can J Cardiol 2020;36:635-647. https://doi.org/10.1016/j.cjca.2020.01.013.

  29. Rodriguez-Iturbe B, Pons H, Johnson RJ.Role of the immune system in hypertension.Physiol Rev 2017;97:1127-1164. https://doi.org/10.1152/physrev.00031.2016.

  30. Wenzel UO, Bode M, Köhl J, Ehmke H. Apathogenic role of complement in arterialhypertension and hypertensive end organdamage. Am J Physiol Heart Circ Physiol2017;312:H349-h354. https://doi.org/10.1152/ajpheart.00759.2016.

  31. Singh MV, Chapleau MW, Harwani SC, AbboudFM. The immune system and hypertension.Immunol Res 2014;59:243-253. https://doi.org/10.1007/s12026-014-8548-6.

  32. Sebastián-Domingo J, Sánchez-SánchezC. De la flora intestinal al microbioma. RevEsp Enferm Dig 2018;110:51-56. https://doi.org/10.17235/reed.2017.4947/2017.

  33. Lu D, Huang Y, Kong Y, Tao T, Zhu X. Gutmicroecology: Why our microbes could bekey to our health. Biomed Pharmacother2020;131:110784. https://doi.org/10.1016/j.biopha.2020.110784.

  34. Singh RK, Chang HW, Yan D, Lee KM, UcmakD, Wong K, et al. Influence of diet on thegut microbiome and implications for humanhealth. J Transl Med 2017;15:73. https://doi.org/10.1186/s12967-017-1175-y.

  35. Alcock J, Lin HC. Fatty acids from diet and microbiotaregulate energy metabolism. F1000Res2015;4:738. https://doi.org/10.12688/f1000research.6078.1.

  36. Álvarez-Vega M, Cortés-Badilla MV, Quirós-Mora LM. El impacto de la microbiota en laenfermedad cardiovascular. Rev Méd Sinerg2021;6:e643. https://doi.org/10.31434/rms.v6i2.643.

  37. Naqvi S, Asar TO, Kumar V, Al-Abbasi FA,Alhayyani S, Kamal MA, et al. A cross-talkbetween gut microbiome, salt and hypertension.Biomed Pharmacother 2021;134:111156.https://doi.org/10.1016/j.biopha.2020.111156.

  38. Mansour SR, Moustafa MA, Saad BM, HamedR, Moustafa AA. Impact of diet on humangut microbiome and disease risk. New MicrobesNew Infect 2021;41:100845. https://doi.org/10.1016/j.nmni.2021.100845.

  39. Muralitharan RR, Jama HA, Xie L, Peh A,Snelson M, Marques FZ. Microbial peer pressure:The role of the gut microbiota in hypertensionand its complications. Hypertension2020;76:1674-1687. https://doi.org/10.1161/hypertensionaha.120.14473.

  40. Tang WH, Bäckhed F, Landmesser U, HazenSL. Intestinal microbiota in cardiovascular healthand disease: JACC state-of-the-art review. J AmColl Cardiol 2019;73:2089-2105. https://doi.org/10.1016/j.jacc.2019.03.024.

  41. Arredondo-Bruce A, Guerrero-Jiménez G,Arredondo-Rubido A. Relación entre la microbiotadel intestino y la tensión arterial. MEDISAN2019;23:967-980.

  42. Jama HA, Beale A, Shihata WA, Marques FZ.The effect of diet on hypertensive pathology: isthere a link via gut microbiota-driven immunometabolism?Cardiovasc Res 2019;115:1435-1447. https://doi.org/10.1093/cvr/cvz091.

  43. Duttaroy AK. Role of gut microbiota andtheir metabolites on atherosclerosis, hypertensionand human blood platelet function:A review. Nutrients 2021;13:144. https://doi.org/10.3390/nu13010144.

  44. Sircana A, De Michieli F, Parente R, Framarin L,Leone N, Berrutti M, et al. Gut microbiota, hypertensionand chronic kidney disease: Recentadvances. Pharmacol Res 2019;144:390-408.https://doi.org/10.1016/j.phrs.2018.01.013.

  45. Honour J. The possible involvement of intestinalbacteria in steroidal hypertension. Endocrinology1982;110:285-287. https://doi.org/10.1210/endo-110-1-285.

  46. Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G,et al. Gut microbiota dysbiosis contributes tothe development of hypertension. Microbiome2017;5:14. https://doi.org/10.1186/s40168-016-0222-x.

  47. Desvarieux M, Demmer RT, Jacobs DR,Jr., Rundek T, Boden-Albala B, Sacco RL,et al. Periodontal bacteria and hypertension:the oral infections and vascular diseaseepidemiology study (INVEST). J Hypertens2010;28:1413-1421. https://doi.org/10.1097/HJH.0b013e328338cd36.

  48. Barrows IR, Ramezani A, Raj DS. Inflammation,immunity, and oxidative stress in hypertensionpartnersin crime? Adv Chronic Kidney Dis2019;26:122-130. https://doi.org/10.1053/j.ackd.2019.03.001.

  49. Gomez-Arango LF, Barrett HL, McIntyre HD,Callaway LK, Morrison M, Dekker-Nitert M.Increased systolic and diastolic blood pressureis associated with altered gut microbiota compositionand butyrate production in early pregnancy.Hypertension 2016;68:974-981. https://doi.org/10.1161/hypertensionaha.116.07910.

  50. Oyama JI, Node K. Gut microbiota and hypertension.Hypertens Res 2019;42:741-743.https://doi.org/10.1038/s41440-018-0203-5.

  51. Cox MJ, Cookson WO, Moffatt MF. Sequencingthe human microbiome in health anddisease. Hum Mol Genet 2013;22:R88-94.https://doi.org/10.1093/hmg/ddt398.

  52. Guo Y, Li X, Wang Z, Yu B. Gut microbiota dysbiosisin human hypertension: A systematic reviewof observational studies. Front CardiovascMed 2021;8:650227. https://doi.org/10.3389/fcvm.2021.650227.

  53. Li H, Liu B, Song J, An Z, Zeng X, Li J, et al.Characteristics of gut microbiota in patientswith hypertension and/or hyperlipidemia:A cross-sectional study on rural residents inXinxiang County, Henan Province. Microorganisms2019;7:399. https://doi.org/10.3390/microorganisms7100399.

  54. CD Genomics-MicrobioSeq. Metagenomicshotgun sequencing. NY, USA: CD Genomics;2022. Acceso 13 de octubre de 2022. Disponibleen https://www.cd-genomics.com/microbioseq/metagenomic-shotgun-sequencingplatform.html?gclid=CjwKCAiAvK2bBhB8EiwAZUbP1EVup_zydA1wNMjNcOwO5uwPJgFSkMUDNFl3-Hbh7J3ESXt0MTglPxoC3Z8QAvD_BwE.

  55. López-Causapé C, González-Candelas F,Carmona T, Palomo O. 71. Aplicaciones delas técnicas de secuenciación masiva en laMicrobiología Clínica. In: Cercenado-MansillaE, Cantón-Moreno R, eds. Procedimientos enMicrobiología Clínica: Sociedad Española deEnfermedades Infecciosas y MicrobiologíaClínica (SEIMC); 2021. p. 55. https://seimc.org/contenidos/documentoscientificos/procedimientosmicrobiologia/seimc-procedimiento71.pdf.

  56. Yan Q, Gu Y, Li X, Yang W, Jia L, Chen C, etal. Alterations of the gut microbiome in hypertension.Front Cell Infect Microbiol 2017;7:381.https://doi.org/10.3389/fcimb.2017.00381.

  57. Kim S, Goel R, Kumar A, Qi Y, Lobaton G,Hosaka K, et al. Imbalance of gut microbiomeand intestinal epithelial barrier dysfunctionin patients with high blood pressure.Clin Sci (Lond) 2018;132:701-718. https://doi.org/10.1042/cs20180087.

  58. SYNLAB Colombia. myBIOME. Bogotá D.C.:SYNLAB; 2022. Acceso 15 de octubre de 2022.Disponible en https://www.synlab.co/mybiome/.




2020     |     www.medigraphic.com